How have KSPHF shares performed in 2024?

Kissei Pharmaceutical's stock was trading at $20.89 at the start of the year. Since then, KSPHF stock has increased by 9.5% and is now trading at $22.88. View the best growth stocks for 2024 here .

Are investors shorting Kissei Pharmaceutical?

Kissei Pharmaceutical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 18,300 shares, an increase of 72.6% from the March 15th total of 10,600 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. View Kissei Pharmaceutical's Short Interest .

How do I buy shares of Kissei Pharmaceutical?

Shares of KSPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:KSPHF

Kissei Pharmaceutical (KSPHF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KSPHF Stock Alerts

$22.88

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $22.88
▼
$22.88
50-Day Range: $22.88
▼
$22.88
52-Week Range: $20.89
▼
$22.88

Volume: N/A
Average Volume: 983 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get Kissei Pharmaceutical alerts:

Ad Weiss Ratings

This Little-Known Stock Controls the Future of AI

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is headquartered in Matsumoto, Japan.

KSPHF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KSPHF Stock News Headlines

June 20, 2023 | morningstar.com

Kissei Pharmaceutical Co Ltd

May 18, 2023 | investing.com

Kissei Pharmaceutical Co Ltd (4547)

April 18, 2024 | Weiss Ratings (Ad)

This Little-Known Stock Controls the Future of AI

April 19, 2023 | wsj.com

Kissei Pharmaceutical Co. Ltd.

January 16, 2023 | finance.yahoo.com

Kissei Pharmaceutical Co., Ltd. (KSPHF)

February 3, 2022 | markets.businessinsider.com

Kissei Pharmaceutical is about to announce earnings — here's what Wall Street expects

January 12, 2022 | nasdaq.com

Kissei Pharmaceutical Co. Ltd (KSPHF)

November 10, 2021 | markets.businessinsider.com

What Wall Street expects from Kissei Pharmaceutical's earnings

See More Headlines

Receive KSPHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kissei Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:KSPHF
CUSIP: N/A
CIK: N/A
Web: www.kissei.co.jp
Phone: (126) 325-9081
Fax: N/A
Employees: 1,359
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Mutsuo Kanzawa (Age 75)
Chairman & CEO
Mr. Yasuo Takehana (Age 64)
President, COO & Director
Mr. Takahide Kitahara (Age 62)
GM of Financial Management Department, MD & Director
Mr. Yoshio Furihata (Age 62)
Senior Advisor & Director
Mr. Keiji Fukushima (Age 68)
Executive VP & Director
Mr. Tetsu Takayama (Age 63)
Executive MD & Director
Hiroshi Noake (Age 60)
GM of Pharmaceutical Sales Headquarters & Director
Keiji Miyazawa (Age 57)
GM of Research Division & Director

Key Competitors

View All Competitors

KSPHF Stock Analysis - Frequently Asked Questions

How have KSPHF shares performed in 2024?: Kissei Pharmaceutical's stock was trading at $20.89 at the start of the year. Since then, KSPHF stock has increased by 9.5% and is now trading at $22.88.
View the best growth stocks for 2024 here.
Are investors shorting Kissei Pharmaceutical?: Kissei Pharmaceutical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 18,300 shares, an increase of 72.6% from the March 15th total of 10,600 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
View Kissei Pharmaceutical's Short Interest.
How do I buy shares of Kissei Pharmaceutical?: Shares of KSPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:KSPHF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial